Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Luis Feo Bernabe
Preclinical Evaluation of the Novel, Orally Bioavailable Selective Inhibitor of Nuclear Export (SINE) KPT-335 in Spontaneous Canine Cancer: Results of a Phase I Study
PLoS ONE
Multidisciplinary
Related publications
Verdinexor (KPT-335), a Selective Inhibitor of Nuclear Export, Reduces RSV Replication in Vitro
Journal of Virology
Insect Science
Immunology
Microbiology
Virology
Ribosomal Biogenesis and Translational Flux Inhibition by the Selective Inhibitor of Nuclear Export (SINE) XPO1 Antagonist KPT-185
PLoS ONE
Multidisciplinary
Selective Inhibitors of Nuclear Export (SINE)– A Novel Class of Anti-Cancer Agents
Journal of Hematology and Oncology
Cancer Research
Oncology
Hematology
Molecular Biology
Discovery and Evaluation of BMS-708163, a Potent, Selective and Orally Bioavailable Γ-Secretase Inhibitor
ACS Medicinal Chemistry Letters
Organic Chemistry
Biochemistry
Drug Discovery
The Pharmacokinetics and Safety of ABT-751, a Novel, Orally Bioavailable Sulfonamide Antimitotic Agent: Results of a Phase 1 Study
Clinical Cancer Research
Cancer Research
Oncology
Fragment-Based Drug Design and Identification of HJC0123 , a Novel Orally Bioavailable STAT3 Inhibitor for Cancer Therapy
European Journal of Medicinal Chemistry
Medicine
Organic Chemistry
Drug Discovery
Pharmacology
A Phase I Trial and PK Study of Cediranib (AZD2171), an Orally Bioavailable Pan-Vegfr Inhibitor, in Children With Recurrent or Refractory Primary CNS Tumors
Child's Nervous System
Medicine
Child Health
Neurology
Pediatrics
Perinatology
Anti-Tumor Activity of Selective Inhibitor of Nuclear Export (SINE) Compounds, Is Enhanced in Non-Hodgkin Lymphoma Through Combination With mTOR Inhibitor and Dexamethasone
Cancer Letters
Cancer Research
Oncology
Preclinical Investigation of PEGylated Tumor Necrosis Factor in Dogs With Spontaneous Tumors: Phase I Evaluation
Clinical Cancer Research
Cancer Research
Oncology
